Standout Papers

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive... 2005 2026 2012 2019 4.6k
  1. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (2008)
    Paul M. Ridker, Eleanor Danielson et al. New England Journal of Medicine
  2. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein (2009)
    Paul M. Ridker, Eleanor Danielson et al. Obstetrical & Gynecological Survey
  3. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease (2005)
    John C. LaRosa, Scott M. Grundy et al. New England Journal of Medicine
  4. Effects of Torcetrapib in Patients at High Risk for Coronary Events (2007)
    Philip J. Barter, Mark J. Caulfield et al. New England Journal of Medicine
  5. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events (2015)
    Jennifer G. Robinson, Michel Farnier et al. New England Journal of Medicine
  6. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events (2007)
    Philip J. Barter, Antonio M. Gotto et al. New England Journal of Medicine
  7. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (2020)
    Kausik K. Ray, R. Scott Wright et al. New England Journal of Medicine
  8. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients (2016)
    Stephen J. Nicholls, Rishi Puri et al. JAMA
  9. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (2009)
    Paul M. Ridker, Eleanor Danielson et al. The Lancet
  10. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (2017)
    Kausik K. Ray, Ulf Landmesser et al. New England Journal of Medicine
  11. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins (2012)
    S. Matthijs Boekholdt, Benoît J. Arsenault et al. JAMA
  12. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism (2009)
    Robert J. Glynn, Eleanor Danielson et al. New England Journal of Medicine
  13. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (2020)
    Frederick J. Raal, David Kallend et al. New England Journal of Medicine
  14. Evinacumab for Homozygous Familial Hypercholesterolemia (2020)
    Frederick J. Raal, Robert S. Rosenson et al. New England Journal of Medicine
  15. Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019)
    Brian A. Ference, John J.P. Kastelein et al. JAMA
  16. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia (2015)
    John J.P. Kastelein, Henry N. Ginsberg et al. European Heart Journal
  17. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia (2015)
    Daniel Gaudet, Veronica J. Alexander et al. New England Journal of Medicine
  18. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study (2015)
    Danish Saleheen, Robert A. Scott et al. The Lancet Diabetes & Endocrinology
  19. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia (2019)
    Ilse K. Luirink, Albert Wiegman et al. New England Journal of Medicine
  20. The PCSK9 decade (2012)
    Gilles Lambert, Barbara Sjouke et al. Journal of Lipid Research
  21. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome (2014)
    Barbara Sjouke, D. Meeike Kusters et al. European Heart Journal
  22. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis (2021)
    R. Scott Wright, Kausik K. Ray et al. Journal of the American College of Cardiology

Immediate Impact

12 from Science/Nature 140 standout
Sub-graph 1 of 14

Citing Papers

Durable and efficient gene silencing in vivo by hit-and-run epigenome editing
2024 StandoutNature
Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality
2023 Standout
2 intermediate papers

Works of John J.P. Kastelein being referenced

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
2020 Standout
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
2015 Standout
and 7 more

Author Peers

Author Last Decade Papers Cites
John J.P. Kastelein 42487 23640 18600 823 68.7k
Christie M. Ballantyne 28449 16385 19208 1.1k 64.3k
Børge G. Nordestgaard 26288 18383 16415 936 63.7k
Antonio M. Gotto 26174 16038 11477 588 48.9k
Christopher P. Cannon 27182 13675 37120 869 65.6k
Frank M. Sacks 16506 14975 14944 410 61.0k
Marc A. Pfeffer 25888 17255 62884 593 94.5k
Eugene Braunwald 29906 12024 49596 687 75.0k
Marc S. Sabatine 22026 12790 27026 499 49.0k
Philip J. Barter 20207 16133 7888 379 35.4k
Jacques Genest 15748 10316 12801 704 39.5k

All Works

Loading papers...

Rankless by CCL
2026